The FDA issues a warning about the risk of hepatitis B virus reactivation among patients taking direct-acting antivirals to treat hepatitis C infections.
Total alcohol abstinence is the cornerstone of treatment for patients with alcohol use disorders and alcoholic liver disease.
Shortening the duration of HCV therapy from 12 weeks to 3 weeks could substantially reduce the cost of treatment.
Physical Activity reduces intrahepatic lipid content and markers of hepatocellular injury in patients with NAFLD and this effect correlated with baseline body mass index.
In patients with Hepatitis C, Oral treatment with sofosbuvir plus ribavirin is preferred over interferon based triple therapy.
The mortality rate from pancreatic cancer is significantly higher in the American region than in the European and Western Pacific regions.
HCVcAg assays with signal amplification have the potential to replace NAT in settings with high HCV prevalence.
In patients with primary biliary cholangitis obeticholic acid was associated with significant decreases in alkaline phosphatase and total bilirubin levels.
A new hepatology rotation increased the mean comfort level for managing several liver diseases.
Researchers found significant differences on MRI between malignant and benign hypovascular lesions of the liver.
Most cases of chronic pancreatitis in women are from nonalcoholic etiologies, according to researchers.
Patients with G6PD should avoid triggers of oxidative stress.
In a study, 24% of confiscated drug snorting straws tested positive for human blood.
Patients previously treated for HCC have a high risk of tumor recurrence in the long term.
At 12 months, 21.2% of patients had developed de novo gallbladder disease.
Patients with HIV infection and elevated viral load are likely to progress to advanced hepatic fibrosis.
The combination drug treats 6 strains of chronic hepatitis C.
Older teen adolescents who are overweight are at an increased risk of developing liver cirrhosis later in life.
A clinical practice guideline offers recommendations on the best course of treatment for patients with potentially treatable pancreatic cancer.
Patients with hepatitis C who had a multidisciplinary team during treatment had improved outcomes.
Median overall survival was 11.9 months in patients receiving gemcitabine plus erlotinib.
The FDA has approved Ocaliva to treat patients with primary biliary cholangitis who have not responded or are intolerant to ursodeoxycholic acid.
Patients who underwent orthotopic liver transplants were less likely to be readmitted to the hospital when treated via a specialized protocol.
Direct-acting antivirals pose challenges in patients with hepatitis C and prior hepatocellular carcinoma
The source of a patient's liver transplant did not significantly affect rates of disease recurrence.
Nearly 85% of patients achieved significant pain relief at 1-year follow up.
Patients with acute liver failure have experienced increased survival rates since 1998, a change that applies to both transplant-free and post-transplant patients.
High gluten intake during the first 2 years of life was associated with an increased risk of celiac disease during childhood.
Treatment guidelines must expand to focus on patients co-infected with both HCV and HIV.
Patients with HCV/HIV coinfections had a much higher risk of HCV recurrence.